公开(公告)号：US20210087186A1

公开(公告)日：2021-03-25

申请号：US16961476

申请日：2019-01-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuta TANAKA ,  Tomohiro OHASHI ,  Zenichi IKEDA ,  Yuta TANAKA ,  Florian PÜNNER ,  Takeshi YAMAMOTO ,  Keiko KAKEGAWA ,  Fumiaki KIKUCHI ,  Nao MORISHITA ,  Takahito KASAHARA ,  Masaki SETO ,  Minoru NAKAMURA ,  Kazuaki TAKAMI ,  Masataka MURAKAMI ,  Masaki DAINI ,  Satoshi MIKAMI ,  Minoru SASAKI

IPC: C07D471/04 ,  C07D495/04 ,  C07D487/04 ,  C07D491/048 ,  C07D519/00

Abstract: The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I) wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20230278999A1

公开(公告)日：2023-09-07

申请号：US17819818

申请日：2022-08-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tomoaki HASUI ,  Shinji NAKAMURA ,  Satoshi MIKAMI ,  Tohru YAMASHITA

IPC: C07D471/04 ,  C07D407/12 ,  C07D413/10 ,  C07D413/14

CPC classification number: C07D471/04 ,  C07D407/12 ,  C07D413/10 ,  C07D413/14

Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer’s disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like.
The present invention relates to a compound represented by the formula (I):





wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20220274982A1

公开(公告)日：2022-09-01

申请号：US17630840

申请日：2020-07-28

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuta TANAKA ,  Yuta TANAKA ,  Fumiaki KIKUCHI ,  Takeshi YAMAMOTO ,  Minoru NAKAMURA ,  Kazuaki TAKAMI ,  Masataka MURAKAMI ,  Masaki DAINI ,  Yasufumi WADA ,  Keiko KAKEGAWA ,  Takahito KASAHARA ,  Tomohiro OHASHI ,  Junsi WANG ,  Zenichi IKEDA ,  Florian PUENNER ,  Masaki SETO ,  Satoshi MIKAMI ,  Minoru SASAKI

IPC: C07D471/04

Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US20200270243A1

公开(公告)日：2020-08-27

申请号：US16753613

申请日：2018-10-04

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shinji NAKAMURA ,  Satoshi MIKAMI ,  Tomoaki HASUI ,  Tohru YAMASHITA ,  Shinji MORIMOTO ,  Hidekazu TOKUHARA ,  Norio OYABU ,  Masami YAMADA ,  Atsuko OCHIDA ,  Kazuaki TAKAMI ,  Xin LIU

IPC: C07D471/04 ,  C07D519/00 ,  C07D487/04 ,  A61K9/20

Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20200207734A1

公开(公告)日：2020-07-02

申请号：US16633960

申请日：2018-08-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi KAJITA ,  Satoshi MIKAMI ,  Yuhei MIYANOHANA ,  Tatsuki KOIKE ,  Masaki DAINI ,  Norio OYABU ,  Masaki OGINO ,  Kohei TAKEUCHI ,  Yoshiteru ITO ,  Norihito TOKUNAGA ,  Takahiro SUGIMOTO ,  Tohru MIYAZAKI ,  Tsuneo ODA ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Keisuke IMAMURA

IPC: C07D401/06 ,  C07D211/56 ,  C07D401/10 ,  C07D405/10 ,  C07D207/14 ,  C07D417/06 ,  C07D405/12 ,  C07D409/10 ,  C07D413/06 ,  C07D401/14 ,  C07D205/04 ,  A61P25/26

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.